--- title: "C4 Therapeutics Realigns Finance Leadership After Officer Departure" type: "News" locale: "en" url: "https://longbridge.com/en/news/286617295.md" description: "C4 Therapeutics announced the departure of Chief Accounting Officer Mark Mossler, effective May 15, 2026, with no reported disagreements. CFO Kendra R. Adams will take on the role of principal accounting officer, indicating a streamlined finance leadership structure. This transition suggests operational stability in financial governance. Analysts rate C4 Therapeutics stock (CCCC) as a Buy with a $10.00 price target, though concerns about financial performance persist." datetime: "2026-05-15T21:12:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286617295.md) - [en](https://longbridge.com/en/news/286617295.md) - [zh-HK](https://longbridge.com/zh-HK/news/286617295.md) --- # C4 Therapeutics Realigns Finance Leadership After Officer Departure ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks C4 Therapeutics ( (CCCC) ) just unveiled an update. C4 Therapeutics, Inc. announced that on May 12, 2026, it decided Chief Accounting Officer Mark Mossler will leave his role effective May 15, 2026, with the company stating his departure is not related to any disagreement over financial reporting, operations, policies or practices. Effective the same date, Chief Financial Officer, Head of Corporate Affairs and Treasurer Kendra R. Adams will assume the additional role of principal accounting officer without changes to her existing compensation or arrangements, signaling a continuity-focused, internal realignment of the company’s finance leadership structure. The consolidation of accounting responsibilities under Adams, whose experience and contractual details were previously disclosed in the company’s 2026 proxy filing, suggests C4 Therapeutics is streamlining its senior financial oversight without adding cost at the executive level. For investors and other stakeholders, the absence of reported disputes around Mossler’s departure and the reliance on an existing executive for the principal accounting role point to operational stability in the company’s financial governance despite the leadership transition. The most recent analyst rating on (CCCC) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page. **Spark’s Take on CCCC Stock** According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral. Overall score is held back primarily by weak financial performance (large ongoing losses and significant cash burn) despite manageable leverage. Technicals are supportive but overbought, and valuation is difficult given negative earnings. Corporate events are a clear positive due to pipeline progress and the Roche collaboration. To see Spark’s full report on CCCC stock, click here. **More about C4 Therapeutics** C4 Therapeutics, Inc. is a biotechnology company focused on developing targeted protein degrader therapies, operating in the biopharmaceutical industry. The company concentrates on designing small-molecule medicines that harness the body’s natural protein degradation mechanisms to treat cancer and other serious diseases, targeting unmet medical needs in specialized therapeutic markets. **Average Trading Volume:** 3,065,325 **Technical Sentiment Signal:** Buy **Current Market Cap:** $401.4M For a thorough assessment of CCCC stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [CCCC.US](https://longbridge.com/en/quote/CCCC.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md) - [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md) ## Related News & Research - [](https://longbridge.com/en/news/286273737.md) - [12:06 ETGenScript Launches TurboCHO™ Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class](https://longbridge.com/en/news/286130384.md) - [C4 Therapeutics Q1 revenue beats estimates on Biogen milestone payment](https://longbridge.com/en/news/286086765.md) - [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md) - [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)